FINWIRES · TerminalLIVE
FINWIRES

$MCK

28 stories mentioning MCKUpdated just now

Every FINWIRES story that references MCK, newest first.

What are analysts saying about MCK?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on MCK?

Wire

McKesson Continues to Face Medium-Term Headwinds From Declining Employer Coverage of GLP-1, RBC Says

McKesson (MCK) continues to face medium-term headwinds from reductions in employers' coverage of GLP-1 medications, which could be partially offset by the Medicare GLP-1 Bridge program, RBC Capital Markets said in a Monday note.The program has enrolled about 600,000 Medicare beneficiaries since its launch in July and is expected to boost income for the company's prescription technologies solutions, the brokerage said. RBC estimates about a $77 million to $102 million contribution to the segment's fiscal 2027 operating income, including second prior authorizations."Gains from the Bridge program will be almost entirely offset by reduced employer coverage," RBC noted. A decline in prior authorizations of 15% to 20% would risk about $50 million to $100 million in the prescription technologies solutions segment's operating income, RBC added.RBC maintained its sector perform rating on McKesson, with a price target of $845.Price: $894.67, Change: $+13.16, Percent Change: +1.49%

$MCK
Update: Equities Rise Despite US-Canada Trade Tensions
US Markets

Update: Equities Rise Despite US-Canada Trade Tensions

(Updates with market moves at the end of the day, and other changes, if any.)Stocks rose Tuesday as Wall Street appeared to dismiss rising trade tensions between the US and Canada.The technology-heavy Nasdaq Composite added 0.7% to close at 26,151.30, while the S&P 500 climbed 0.3% to 7,677.28. The Dow Jones Industrial Average advanced 0.3% to settle at 53,577.40, extending its winning streak to a third day.Most sectors were in the green, led by tech, while energy saw the steepest decline.Canada on Tuesday announced retaliatory tariffs on roughly US$20 billion worth of the American goods, matching Washington's move "dollar for dollar."Trade talks between the US and Canada collapsed late last week.West Texas Intermediate crude oil fell 4.6% to $81.10 a barrel in Tuesday late-afternoon trade, while Brent slumped 5.3% to $87.31.On Monday, the US Treasury Department launched an economic campaign to cut off financial channels that support Iran. Tehran expressed confidence that its major trading partners that include China, Russia and India will resist Washington's pressure campaign, according to CNBC.China said its cooperation with Tehran should not be disrupted, CNN reported Tuesday."The market seems largely unfazed by Washington's push for tighter economic pressure on Iran, with traders treating the US effort to nudge partners away from Iranian trade as marginal rather than market-moving," ING Bank said in a report.US Treasury yields were lower, with the 10-year yield down 7.9 basis points at 4.63% and the two-year yield falling six basis points to 4.18%.In economic news, US consumer confidence fell in August amid a decline in the expectations index, with a "more pessimistic" outlook for business conditions and the labor market ahead, the Conference Board said.New home sales in the US decreased more than projected last month even as median prices moved lower, government data showed.Switching to monetary policy, the Federal Reserve may have to raise interest rates soon, unless inflation continues to cool, Boston Fed President Susan Collins said.Markets are currently pricing in a 66% probability that the Fed will keep its benchmark rate steady in September, with the remaining odds in favor of a 25-basis-point hike, according to the CME FedWatch tool.In company news, Dick's Sporting Goods (DKS) shares sank nearly 31%. The athletic goods retailer lowered its full-year outlook amid a challenging athletic footwear and apparel marketplace, while its fiscal second-quarter results fell short of market estimates.McKesson (MCK) agreed to acquire Precision Medicine in a transaction worth roughly $2.25 billion as part of the drug distributor's efforts to strengthen its clinical research and commercialization services. McKesson shares jumped 3.6%.Nvidia (NVDA) shares rose 2.2%, the second-biggest gain on the Dow and snapping a seven-day losing streak. The tech bellwether is scheduled to release its quarterly results on Wednesday.Spot gold was up 0.4% at $4,668.41 per troy ounce, while silver rose 0.5% to $69.76 per ounce.

Dow JonesNasdaq CompositeS&P 500$DKS$MCK$NVDA
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In sector news, the US Department of Health and Human Services is planning to create two deputy commissioner roles at the Food and Drug Administration to focus on technology and drugs, respectively, CNBC reported Tuesday. Specifically, the technology deputy commissioner role would focus on the intersection of health and AI, the report said. HHS officials would appoint the new deputies in what some within the Trump administration view as an attempt to wield greater influence over the agency, CNBC reported.In corporate news, McKesson (MCK) agreed to buy Precision Medicine Group for $2.25 billion as part of the drug distributor's efforts to boost its clinical research and commercialization services. McKesson shares rose 3.1%.Anavex Life Sciences (AVXL) shares surged 14% after the company's fiscal Q3 swung to profits.Kura Oncology (KURA) shares jumped past 9% in Tuesday trading, a day after a regulatory filing showed CEO Troy Wilson purchased 100,000 shares at a weighted average price of $12.39.Jazz Pharmaceuticals (JAZZ) shares added 1.8% after the company said the US Food and Drug Administration approved two of its Ziihera-containing regimens to treat adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of cancer.

$AVXL$JAZZ$KURA$MCK
Update: Equities Rise Intraday, Oil Falls as Markets Monitor Trade Developments
US Markets

Update: Equities Rise Intraday, Oil Falls as Markets Monitor Trade Developments

(Updates with latest market prices and developments.)US benchmark equity indexes were higher intraday, while oil prices dropped as investors tracked Washington's new economic sanctions on Iran and a worsening trade conflict with Canada.The technology-heavy Nasdaq Composite was up 0.5% at 26,118.8 after midday Tuesday, while the S&P 500 rose 0.2% to 7,668.7. The Dow Jones Industrial Average edged up 0.1% to 53,484.3. Among sectors, tech paced the gainers, while consumer staples led the laggards.West Texas Intermediate crude oil fell 3.2% to $82.31 a barrel, while Brent dropped 3.7% to $88.81.On Monday, the US Treasury Department launched an economic campaign to cut off financial channels that support Iran. Countries doing business with Tehran will be given deadlines to shut down Iran-related activities, while entities aiding money laundering or sanctions evasion on behalf of Iran could be cut off from the US financial system.Iran vowed to retaliate and expressed confidence that its major trading partners will resist Washington's pressure campaign, according to CNBC. China, Russia, India, Pakistan, Qatar and Turkey, among others, still trade with Tehran, Axios reported Monday.China has warned that the new US sanctions on Iran "will only further intensify tensions" and that Beijing's cooperation with Tehran should not be disrupted, CNN reported Tuesday."The market seems largely unfazed by Washington's push for tighter economic pressure on Iran, with traders treating the US effort to nudge partners away from Iranian trade as marginal rather than market-moving," ING Bank said in a report.Canada unveiled retaliatory tariffs against Washington, matching "dollar for dollar" the 50% duties recently imposed by US President Donald Trump, news outlets reported Tuesday. Canada's new tariffs reportedly cover more than 700 US goods and are worth roughly $20 billion.Trade talks between the US and Canada collapsed late last week.US Treasury yields were lower intraday Tuesday, with the 10-year yield down 5.9 basis points at 4.65% and the two-year yield falling 2.8 basis points to 4.21%. Yields on long-term maturities also eased.In economic news, US consumer confidence fell in August amid a decline in the expectations index, with a "more pessimistic" outlook for business conditions and the labor market ahead, the Conference Board said.The Federal Reserve may have to tighten its monetary policy soon, unless inflation continues to cool, Boston Fed President Susan Collins said."Given the many possible scenarios, policy will need to be nimble," she said. "Should evidence of sustained inflation progress not materialize, I believe it will be appropriate to tighten policy soon to ensure we deliver price stability in a reasonable time frame."Markets are currently pricing in a 60% probability that the Fed will keep its benchmark rate steady in September, with the remaining odds in favor of a 25-basis-point hike, according to the CME FedWatch tool.In company news, Dick's Sporting Goods (DKS) shares sank 29% intraday. The athletic goods retailer lowered its full-year outlook amid a challenging athletic footwear and apparel marketplace, while its fiscal second-quarter results fell short of market estimates.McKesson (MCK) agreed to acquire Precision Medicine in a transaction worth roughly $2.25 billion as part of the drug distributor's efforts to strengthen its clinical research and commercialization services. McKesson shares were up 2.3%.Intuit (INTU) is among the companies that are scheduled to report their latest quarterly financial results after the closing bell Tuesday.Spot gold was down 0.3 at $4,640.49 per troy ounce, while silver edged up 0.1% to $69.43 per ounce.

Dow JonesNasdaq CompositeS&P 500$DKS$INTU$MCK
Sectors

Sector Update: Healthcare Stocks Advance Tuesday Afternoon

Healthcare stocks rose Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each gaining 0.4%.The iShares Biotechnology ETF (IBB) climbed 2%.In corporate news, McKesson (MCK) agreed to buy Precision Medicine Group for $2.25 billion as part of the drug distributor's efforts to boost its clinical research and commercialization services. McKesson shares rose 2.2%.Jazz Pharmaceuticals (JAZZ) shares gained 3.1% after the company said the US Food and Drug Administration approved two of its Ziihera-containing regimens to treat adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of cancer.Immatics (IMTX) shares climbed 5.4% after the company agreed to sell ordinary shares and pre-funded warrants in an underwritten offering expected to generate $150 million in gross proceeds.

$IMTX$JAZZ$MCK
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.5%.The iShares Biotechnology ETF (IBB) climbed 1.9%.In corporate news, McKesson (MCK) has agreed to buy Precision Medicine in a deal worth about $2.25 billion as part of the drug distributor's efforts to boost its clinical research and commercialization services. McKesson shares rose 1.7%.

$MCK
McKesson to Buy Precision Medicine in $2.25 Billion Deal
US Markets

McKesson to Buy Precision Medicine in $2.25 Billion Deal

McKesson (MCK) has agreed to acquire Precision Medicine in a transaction worth roughly $2.25 billion as part of the drug distributor's efforts to strengthen its clinical research and commercialization services.Precision Medicine provides clinical research and biopharma commercialization services, McKesson said Tuesday."This acquisition represents another meaningful step in advancing our oncology and multispecialty strategy," McKesson Chief Executive Brian Tyler said in a statement. "Precision Medicine Group brings complementary capabilities that will enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden our clinical service offerings."Regulatory approval is required to complete the deal, following which Precision Medicine will report within McKesson's oncology and multispecialty segment."Joining McKesson provides a compelling opportunity to extend the impact of our clinical and commercial expertise," Precision Medicine CEO Margaret Keegan said. "Together, we will bring a broader set of capabilities to biopharma companies, supporting them through the development and commercialization process."Shares of McKesson edged up 1.3% in Tuesday trade, taking the stock's year-to-date gain to 7.9%.Earlier in August, McKesson reported better-than-expected fiscal first-quarter results, with the oncology and multispecialty business posting an annual revenue gain of 33%. At the time, the company said it expected adjusted earnings in a range of $44.20 to $45 per share for fiscal 2027, indicating growth of 13% to 15%. The current consensus on FactSet is for $44.61.During an earnings call with analysts earlier this month, Chief Financial Officer Kenny Cheung told analysts that "there'll be some M&A along the way," according to a FactSet transcript.Last week, RBC Capital Markets said that McKesson's specialty drug exposure and its integrated business model should help offset regulatory pricing pressure.In June, Apollo Global Management (APO) invested $1.25 billion in McKesson's medical-surgical solutions unit for a 13% stake in the business. McKesson plans to separate the division into a publicly traded company.Price: $884.73, Change: $+10.94, Percent Change: +1.25%

$MCK
Wire

McKesson's Specialty Drug Mix Helps Cushion Pricing Pressure, RBC Says

McKesson's (MCK) specialty drug exposure and integrated business model should help offset regulatory pricing pressure, though near-term GLP-1-related headwinds may weigh on growth in its insurance-processing segment, RBC Capital Markets said Wednesday in a report.RBC expects specialty drugs to account for more than 55% of total drug spending by 2028 and said biosimilar introductions may add $250 million in operating income by that year.Inflation Reduction Act pricing changes are expected to create a 70-basis-point revenue headwind, while reduced employer coverage for GLP-1 drugs may pressure prior-authorization activity and cut operating-income growth in its services segment by 5% to 10%, the report said.RBC also cited risks from pharmacy benefit managers steering prescriptions toward "captive specialty pharmacies" as more generic biologics enter the market.RBC initiated coverage of McKesson stock with a sector perform rating and an $845 price target.Price: $863.85, Change: $-5.41, Percent Change: -0.62%

$MCK
Research

RBC Initiates McKesson at Sector Perform With $845 Price Target

McKesson (MCK) has an average rating of overweight and mean price target of $988.19, according to analysts polled by FactSet.

$MCK
Wire

Barclays Raises Price Target on McKesson to $1,000 From $925, Maintains Overweight Rating

McKesson (MCK) has an average rating of buy and mean price target of $997.73, according to analysts polled by FactSet.Price: $877.73, Change: $+17.70, Percent Change: +2.06%

$MCK
Insider Trading

Mckesson Insider Sold Shares Worth $268,590, According to a Recent SEC Filing

Bradley E Lerman, Director, on August 10, 2026, sold 301 shares in Mckesson (MCK) for $268,590.SEC Filing:https://www.sec.gov/Archives/edgar/data/927653/000092765326000239/xslF345X05/form4.xmlPrice: $896.38, Change: $+16.51, Percent Change: +1.88%

$MCK
Wire

Mizuho Adjusts Price Target on McKesson to $905 From $885

McKesson (MCK) has an average rating of buy and mean price target of $985.40, according to analysts polled by FactSet.Price: $841.82, Change: $-35.41, Percent Change: -4.04%

$MCK
Stocks Rise Pre-Bell Amid Growing Hopes for Hormuz Deal; Traders Await More Corporate Earnings
US Markets

Stocks Rise Pre-Bell Amid Growing Hopes for Hormuz Deal; Traders Await More Corporate Earnings

The benchmark US stock measures were trending higher in Wednesday's premarket activity amid growing optimism over a potential deal to reopen the Strait of Hormuz, while investors await the latest batch of corporate earnings.The S&P 500 and the Dow Jones Industrial Average rose 0.3% each before the opening bell, while the Nasdaq edged up 0.1%. The S&P 500 and the Dow recorded fresh all-time highs on Tuesday, while the Nasdaq advanced for a fourth consecutive session.President Donald Trump reportedly said late Tuesday that an agreement to reopen the Strait of Hormuz, the world's most important chokepoint for crude flows, is imminent, following "very good discussions" with Iran, according to CNBC.Treasury Secretary Scott Bessent told CNBC on Tuesday that a potential deal to open the crucial waterway could be reached this week. Qatar's Foreign Ministry spokesperson Majed al-Ansari reportedly said that efforts to resolve the US-Iran conflict are "in very progressive stages."West Texas Intermediate crude oil increased 1.1% to $76.58 a barrel in premarket action, while Brent gained 1.7% to $80.73.Yemen's Iran-aligned Houthis reportedly claimed an attack on a Saudi Arabian tanker near the coast of Yanbu, a major port for Saudi crude oil exports, according to a separate CNBC report.Treasury yields were mixed before the open, with the two-year rate rising 1.2 basis points to 4.21% while the 10-year rate retreated 1 basis point to 4.62%.Eli Lilly (LLY), Walt Disney (DIS), Shopify (SHOP), Uber Technologies (UBER), CVS Health (CVS), Phillips 66 (PSX), Kraft Heinz (KHC) and Global Payments (GPN) are scheduled to report their latest financial results before the bell, among others.Sandisk (SNDK), AppLovin (APP), McKesson (MCK), DoorDash (DASH), eBay (EBAY) and Expedia (EXPE) post their earnings after the markets close.Shares of SpaceX (SPCX) dropped 12% pre-bell after the rocket and satellite company reported quarterly results for the first time since going public. Advanced Micro Devices (AMD) fell 8.6% even though it recorded fiscal second-quarter results above market estimates. Arista Networks (ANET) jumped 16%.Wednesday's economic calendar has the weekly mortgage applications bulletin at 7 am ET, followed by the ADP Employment report for July at 8:15 am. The purchasing managers' index composite final report from S&P Global (SPGI) for July is out at 9:45 am, followed by the Institute for Supply Management's services index for the same month at 10 am.The domestic EIA petroleum inventories report is due at 10:30 am.Federal Reserve Governor Lisa Cook is scheduled to speak at 4:05 pm, while San Francisco Fed President Mary Daly speaks at 8:35 pm.Gold gained 1.5% to $4,215 per troy ounce, while bitcoin slipped 0.2% to $64,146.

Dow JonesNasdaq CompositeS&P 500$AMD$ANET$APP$CVS$DASH$DIS$EBAY$EXPE$GPN$KHC$LLY$MCK$PSX$SHOP$SNDK$SPCX$SPGI$UBER
Insider Trading

Mckesson Insider Sold Shares Worth $6,559,925, According to a Recent SEC Filing

Brian S. Tyler, Director, Chief Executive Officer, on June 17, 2026, sold 8,463 shares in Mckesson (MCK) for $6,559,925. Following the Form 4 filing with the SEC, Tyler has control over a total of 14,598 common shares of the company, with 14,382 shares held directly and 216 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/927653/000092765326000175/xslF345X05/form4.xmlPrice: $756.09, Change: $-23.71, Percent Change: -3.04%

$MCK
Insider Trading

Mckesson Insider Sold Shares Worth $604,420, According to a Recent SEC Filing

Thomas L Rodgers, Executive Vice President, Chief Strategy and Business Development Officer, on June 01, 2026, sold 822 shares in Mckesson (MCK) for $604,420. Following the Form 4 filing with the SEC, Rodgers has control over a total of 2,268 common shares of the company, with 2,268 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/927653/000092765326000138/xslF345X05/form4.xmlPrice: $735.66, Change: $-1.12, Percent Change: -0.15%

$MCK
Insider Trading

Mckesson Insider Sold Shares Worth $1,331,255, According to a Recent SEC Filing

LeAnn B Smith, Executive Vice President & Chief Human Resources Officer, on June 01, 2026, sold 1,810 shares in Mckesson (MCK) for $1,331,255. Following the Form 4 filing with the SEC, Smith has control over a total of 4,798 common shares of the company, with 4,798 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/927653/000092765326000136/xslF345X05/form4.xmlPrice: $734.24, Change: $-0.59, Percent Change: -0.08%

$MCK
Insider Trading

Mckesson Insider Sold Shares Worth $1,817,483, According to a Recent SEC Filing

Thomas L Rodgers, Executive Vice President, Chief Strategy & Business Development Officer, on May 23, 2026, sold 2,388 shares in Mckesson (MCK) for $1,817,483. Following the Form 4 filing with the SEC, Rodgers has control over a total of 3,090 common shares of the company, with 3,090 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/927653/000092765326000124/xslF345X05/form4.xmlPrice: $754.78, Change: $+0.38, Percent Change: +0.05%

$MCK
Insider Trading

Mckesson Insider Sold Shares Worth $2,701,870, According to a Recent SEC Filing

Michele Lau, Executive Vice President and Chief Legal Officer, on May 26, 2026, sold 3,550 shares in Mckesson (MCK) for $2,701,870. Following the Form 4 filing with the SEC, Lau has control over a total of 3,386 common shares of the company, with 3,247 shares held directly and 139 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/927653/000092765326000128/xslF345X05/form4.xmlPrice: $754.54, Change: $+0.14, Percent Change: +0.02%

$MCK
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Mckesson Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $860 from $1,080, 19.4x our FY 27 EPS estimate (up $0.11 to $44.24; FY 28 estimate begins at $50.19), a above peers and MCK's three-year forward average of 18.6x, supported by a stronger margin profile and faster near-term EPS and dividend growth expectations within a favorable environment for pharma distributors, in our view. Looking ahead to FY 27, we expect broad-based growth across core pharma distribution, oncology and multispecialty, and Rx Technology, with more modest growth in Medical-Surgical, supporting overall sales growth near 7%, following 12% growth in FY 26. We attribute the sales growth slowdown to difficult comparisons as well as lower branded drug pricing as certain Inflation Reduction Act provisions take effect. Oncology and multispecialty should produce the strongest profitability growth during FY 27, in our view, followed by the Rx Technology business and core pharma distribution, driving overall adjusted EBIT growth near 9%.

$MCK
Wire

McKesson's Fiscal 2027 Guidance 'Encouraging,' Cencora Selloff Overdone, Morgan Stanley Says

McKesson's (MCK) fiscal 2027 guidance is "encouraging," and its commentary on biosimilars should help ease recent pressure on drug distributors, Morgan Stanley said in a Friday note.The investment firm said McKesson's targets and underlying assumptions support their bullish outlook on distributors that continue to benefit from structural tailwinds.On Cencora (COR), the brokerage said the company faces idiosyncratic contract dynamics with Express Scripts that could lead to continued insourcing of biosimilar specialty drugs and add an overhang to the stock. The recent pullback in Cencora shares was overdone, according to the note.Morgan Stanley raised their fiscal 2026 adjusted earnings estimate on Cencora to $17.76 from $17.63. Analysts surveyed by FactSet expect $17.73.Morgan Stanley has an overweight rating and a $966 price target on McKesson.The firm reiterated its overweight rating on Cencora and lowered its price target to $342 from $400.Price: $265.08, Change: $+9.42, Percent Change: +3.68%

$COR$MCK

Showing 1-20 of 28

Track with the FINWIRES app suite